IMUX250117P1000
- 0.10
- 0.000.00%
イミューニックのニュース一覧
Immunic CEO Dr Daniel Vitt on Successful 2024, With More to Come in the Year Ahead | NASDAQ:IMUX
Immunic CSO Discusses Breaking the IBD Stigma to Mark Crohn's and Colitis Awareness Week | NASDAQ:IMUX
B.ライリー・フィナンシャルはイミューニック(IMUX.US)のレーティングを強気に据え置き、目標株価を6ドルに据え置いた
B.ライリー・フィナンシャルのアナリストWilliam Woodは$Immunic(IMUX.US)$のレーティングを強気に据え置き、目標株価を6ドルに据え置いた。TipRanksのデータによると、このアナリストの最近1年間の的中率は47.6%、平均リターンは12.2%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情報を提供している独立第
Immunic, Inc. to Participate in Investor Conference in December
Immunic Price Target Announced at $10.00/Share by HC Wainwright & Co.
Insider Buys Additional US$100k In Immunic Stock
Immunic Announces Publication of IMU-856 Data
Immunic Reports Positive Phase 1 Results for Celiac Disease Therapy Published in The Lancet | NASDAQ:IMUX
Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript Summary
Immunic CEO Details Progress Following Productive Third Quarter | NASDAQ:IMUX
イミューニック | 10-Q：Q3 2024 四半期報告書
イミューニック | 8-K：Immunic, Inc. は、2024年第3四半期の決算を報告し、企業最新情報を提供します
Immunic: Q3 Earnings Snapshot
Immunic's Cash And Cash Equivalents As Of September 30, Were $59.1M, Expected To Provide Cash Runway Into Q3 Of 2025
Immunic Q3 2024 GAAP EPS $(0.24) Misses $(0.22) Estimate
Press Release: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic 3Q Loss $24.4M >IMUX
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic's Jessica Breu Talks BIO-Europe & MS Research Advancements | NASDAQ:IMUX
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update